CHICAGO, July 16 (Reuters) - An experimental Alzheimer's disease drug developed by Acumen Pharmaceuticals (ABOS.O) targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday.
The drug, ACI193, was well tolerated in the first trial testing it in people, the company said.
Results of the randomized, placebo-controlled study of 62 patients with early Alzheimer's disease were presented at the Alzheimer's Association's International Conference in Amsterdam.
In the Acumen trial, 10.4% of treated participants (5 people) developed a brain swelling condition known as ARIA-E associated with amyloid-targeting treatments.
Acumen said the study suggests the drug can be given as a monthly intravenous infusion.
Eric Siemers, Leqembi, Julie Steenhuysen, Bill Berkrot